MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation
8 March 2018

MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation

MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in...

Read the press release